Let's break down Glenmark Pharmaceuticals Ltd. (GLENMARK) — from its financial performance to how the market is valuing the stock.
Glenmark Pharma Revenue Trend
A 5.3% jump in revenue took Glenmark Pharmaceuticals Ltd.'s top line to ₹13,322 Cr in FY2025.
Glenmark Pharmaceuticals Ltd.'s revenue compounded at 7.2% over 10 years — not a breakout compounder, but steady enough to suggest a stable business.
In terms of scale, Glenmark Pharmaceuticals Ltd.'s ₹13,322 Cr in annual revenue positions it as a major pharmaceuticals company.
| Year | Revenue | YoY % |
|---|---|---|
| FY2025 | ₹13,322 Cr | +5.3% |
| FY2024 | ₹12,653 Cr | +9.2% |
| FY2023 | ₹11,583 Cr | -7.1% |
| FY2022 | ₹12,472 Cr | +14.0% |
| FY2021 | ₹10,944 Cr | — |
View Glenmark Pharmaceuticals Ltd.'s full 10-year revenue trend with CAGR analysis →
Glenmark Pharma Profitability
Diluted EPS came in at ₹37.11 for FY2025, up from ₹-53.22 a year earlier.
Is Glenmark Pharma Undervalued
Per the P/E Ratio model, Glenmark Pharmaceuticals Ltd. has an estimated intrinsic value of ₹1,435 (34.0% downside).
Glenmark Pharmaceuticals Ltd. shares are currently trading at ₹2,174.00.
Craytheon also calculates intrinsic value using the EPS Growth model. The full breakdown with assumptions is available in the detailed analysis.
| Model | Est. Fair Value | vs. Current Price |
|---|---|---|
| P/E Ratio | ₹1,435 | 34.0% downside to fair value |
| EPS Growth | Upgrade | Upgrade |
See all valuation models for Glenmark Pharmaceuticals Ltd. with detailed assumptions →
Glenmark Pharma Shareholding Pattern
Promoter holding has remained stable at 46.6% over the past 4 quarters, indicating confidence in the company's direction.
On the foreign institutional side, the holding is 20.3% as of March 2026 — down from 20.6%.
The DII stake stands at 19.3% as of March 2026, versus 17.6% in the year-ago period.
| Quarter | Promoter | FII | DII | Public |
|---|---|---|---|---|
| Mar 2026 | 46.6% | 20.3% | 19.3% | 13.7% |
| Dec 2025 | 46.6% | 19.2% | 20.1% | 14.0% |
| Sep 2025 | 46.6% | 20.7% | 18.6% | 14.0% |
| Jun 2025 | 46.6% | 20.6% | 17.6% | 15.1% |
Track quarterly shareholding changes for Glenmark Pharmaceuticals Ltd. →
Glenmark Pharma Balance Sheet
Proportional view as of 3 Jun 2026. Hover blocks for details.
Assets
Liabilities & Equity
Total assets stood at ₹160.50B at the end of FY2025, up 12.2% from ₹143.09B a year earlier.
Property, Plant & Equipment is the largest block at 22.5%, followed by Receivables at 20.8% and Other Assets at 19.7%.
Equity makes up 55.1% of liabilities and equity, with debt at 15.4% and operating liabilities at 29.5%. Over the year, debt is up 100.9% and equity is up 12.8%.
Balance sheet composition — FY 2025
| Category | Value |
|---|---|
| Cash & ST Investments | 16.76B |
| Receivables | 33.42B |
| Inventories | 30.29B |
| Property, Plant & Equipment | 36.18B |
| Investments | 563.55M |
| Intangibles & Goodwill | 11.67B |
| Other Assets | 31.61B |
| Category | Value |
|---|---|
| Equity | 88.49B |
| Short-term Debt | 17.74B |
| Long-term Debt | 6.99B |
| Trade Payables | 25.80B |
| Other Liabilities | 21.48B |
Glenmark Pharma at a Glance
Here's the bottom line on Glenmark Pharmaceuticals Ltd. (GLENMARK) based on the latest available financials.
Revenue of ₹13,322 Cr in FY2025, up 5.3% year-over-year.
Long-term revenue has been compounding at 7.2% annually over 10 years.
The company is profitable, with a net margin of 7.9% and net income of ₹1,047 Cr.
The P/E Ratio model implies 34.0% downside to fair value from the current price. The remaining two models are worth cross-checking before drawing a conclusion — sign up to see the full analysis.
Unlock Full Analysis
For the complete 10-year financial history with interactive charts and growth analysis, explore Glenmark Pharmaceuticals Ltd.'s detailed profile on Craytheon.